TY - JOUR
T1 - Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016
T2 - a systematic analysis for the Global Burden of Disease Study 2016
AU - GBD 2016 Lower Respiratory Infections Collaborators
AU - Troeger, Christopher
AU - Blacker, Brigette
AU - Khalil, Ibrahim A.
AU - Rao, Puja C.
AU - Cao, Jackie
AU - Zimsen, Stephanie R.M.
AU - Albertson, Samuel B.
AU - Deshpande, Aniruddha
AU - Farag, Tamer
AU - Abebe, Zegeye
AU - Adetifa, Ifedayo Morayo O.
AU - Adhikari, Tara Ballav
AU - Akibu, Mohammed
AU - Al Lami, Faris Hasan
AU - Al-Eyadhy, Ayman
AU - Alvis-Guzman, Nelson
AU - Amare, Azmeraw T.
AU - Amoako, Yaw Ampem
AU - Antonio, Carl Abelardo T.
AU - Aremu, Olatunde
AU - Asfaw, Ephrem Tsegay
AU - Asgedom, Solomon Weldegebreal
AU - Atey, Tesfay Mehari
AU - Attia, Engi Farouk
AU - Avokpaho, Euripide Frinel G.Arthur
AU - Ayele, Henok Tadesse
AU - Ayuk, Tambe Betrand
AU - Balakrishnan, Kalpana
AU - Barac, Aleksandra
AU - Bassat, Quique
AU - Behzadifar, Masoud
AU - Behzadifar, Meysam
AU - Bhaumik, Soumyadeep
AU - Bhutta, Zulfiqar A.
AU - Bijani, Ali
AU - Brauer, Michael
AU - Brown, Alexandria
AU - Camargos, Paulo A.M.
AU - Castañeda-Orjuela, Carlos A.
AU - Colombara, Danny
AU - Conti, Sara
AU - Dadi, Abel Fekadu
AU - Dandona, Lalit
AU - Dandona, Rakhi
AU - Do, Huyen Phuc
AU - Dubljanin, Eleonora
AU - Edessa, Dumessa
AU - Elkout, Hajer
AU - Endries, Aman Yesuf
AU - Fijabi, Daniel Obadare
N1 - Funding Information:
CATA reports grants and personal fees from Johnson & Johnson (Philippines) Inc, outside the submitted work. BDG reports employment from Pfizer Vaccines during the conduct of the study, and reports grants from GSK, Merck, Pfizer, and Sanofi Pasteur, outside the submitted work. MBJ reports grants from Ministry of Education Science and Technological Development of the Republic of Serbia (grant OI 175014) during the conduct of the study. MJP reports grants and personal fees from AbbVie, Sigma Tau, MSD, GSK, Pfizer, AscA, Boehringer Ingelheim, Novavax, and Ingress Health, grants from Bayer, BMS, Astra Zeneca, Sanofi, and ARTEG, and personal fees from Astellas, Mapi, OptumInsight, Novartis, Swedish Orphan, Innoval, Jansen, Intercept, and Pharmerit; holds 2% of stocks in Ingress Health (a health economics consultancy); and advises two pharmacoeconomics spin-off companies from the University of Groningen. MSav reports employment at GSK Biologicals SA, Wavre, Belgium, from Feb 1, 2018. JAS reports grants from Takeda and Savient, and personal fees from Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Crealta/Horizon, Allergan, UBM LLC, WebMD, and The American College of Rheumatology. Outside the submitted work, JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA Inc (a 501c3 entity), and is a steering committee member of OMERACT, which receives funding from 36 pharmaceutical companies. The other authors declare no competing interests.
Funding Information:
ABa is funded by the Project of Ministry of Education, Science and Technology of the Republic of Serbia (number III45005). SMR would like to acknowledge Contech School of Public Health management for their cooperation. RS reports research funding from the Cystic Fibrosis Foundation, Cystic Fibrosis Canada, Alberta Innovates, and the Canadian Institutes of Health Research.
Publisher Copyright:
© 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
PY - 2018/11/1
Y1 - 2018/11/1
UR - http://www.scopus.com/inward/record.url?scp=85056226781&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056226781&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(18)30310-4
DO - 10.1016/S1473-3099(18)30310-4
M3 - Article
C2 - 30243584
AN - SCOPUS:85056226781
SN - 1473-3099
VL - 18
SP - 1191
EP - 1210
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
IS - 11
ER -